Downward pricing pressure pushes Philips into a slaes-and-revenue decline, as its healthcare business sees a nearly 20% EBITA slide.
Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.
John Flannery's experience in global markets landed him the top spot at GE Healthcare, where he replaced John Dineen, GE CEO Jeffrey Immelt told analysts last week.
Stryker edges expectations on Wall Street despite a nearly 45% profit slide as it posts strong revenue growth and expands its footprint in Europe.
Getinge lowers its sales forecast for the rest of the year amid uncertain earnings outlook, sending share prices plunging in Stockholm.
St. Jude Medical CEO Dan Starks is bullish on the potential for recent acquisition CardioMEMS to tap the $1 billion market for treating heart failure.
Baxter's 3rd-quarter profits beat expectations, driven by its medical product business, but shares slide on a lowered earnings forecast.
(Reuters) - Medical device and drug maker Baxter (NYSE:BAX) reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.